National Aboriginal and Torres Strait Islander cancer framework 2015

Overview The National Aboriginal and Torres Strait Islander Cancer Framework (the Framework) provides high-level guidance and direction for the many individuals, communities, organisations and governments whose combined efforts are required to address disparities and improve cancer outcomes for Aboriginal and Torres Strait Islander peoples. This Framework is designed to complement and enhance national, jurisdictional, regional and local efforts to improve Aboriginal and Torres Strait Islander cancer outcomes, including cancer plans and related policies, frameworks and action plans. It sets out priority areas for action, and allows the flexibility for jurisdictions, communities and organisations to address those priorities in ways that suit their local context and local needs. This Framework encompasses the full continuum of cancer control, including cancer prevention, screening and early detection, diagnosis and treatment, palliative care and survivorship; and the policy, systems, research and infrastructure that surround these service areas

Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Human cancer cells typically harbour multiple chromosomal aberrations, nucleotide substitutions and epigenetic modifications that drive malignant transformation. The Cancer Genome Atlas (TCGA) pilot project aims to assess the value of large-scale multi-dimensional analysis of these molecular characteristics in human cancer and to provide the data rapidly to the research community. Here we report the interim integrative analysis of DNA copy number, gene expression and DNA methylation aberrations in 206 glioblastomas--the most common type of adult brain cancer--and nucleotide sequence aberrations in 91 of the 206 glioblastomas. This analysis provides new insights into the roles of ERBB2, NF1 and TP53, uncovers frequent mutations of the phosphatidylinositol-3-OH kinase regulatory subunit gene PIK3R1, and provides a network view of the pathways altered in the development of glioblastoma. Furthermore, integration of mutation, DNA methylation and clinical treatment data reveals a link between MGMT promoter methylation and a hypermutator phenotype consequent to mismatch repair deficiency in treated glioblastomas, an observation with potential clinical implications. Together, these findings establish the feasibility and power of TCGA, demonstrating that it can rapidly expand knowledge of the molecular basis of cancer

Evaluation of the impact of National Breast Cancer Foundation-funded research

© Copyright 2014. The Medical Journal of Australia - reproduced with permission.Objective: To evaluate the impact of the National Breast Cancer Foundation’s (NBCF’s) research investment. Design and participants: Surveys based on the Payback Framework were sent to chief investigators involved in research funded by the NBCF during 1995–2012; a bibliometric analysis of NBCF-funded publications in 2006–2010 was conducted; and a purposive, stratified sample of case studies was obtained. Main outcome measures: Research impact on knowledge production, the research system, informing policy, product development and broader health and economic benefits. Results: Of 242 surveys sent, 153 (63%) were returned. The average impact of journals in which NBCF publications appeared was double that of world publications. Seventy surveys (46%) reported career progression, and 185 higher degrees were obtained or expected, including 121 PhDs. One hundred and one grants (66%) produced tools that built capacity across the research system, and research teams leveraged an additional $1.40 in funding for every dollar invested. Fifteen applied grants and one basic grant impacted on policy. Ten basic and four applied grants led to the development of drugs, prognostic tools or diagnostic technologies. Twenty applied and two basic grants led to changes in practice and behaviour of health care staff, consumers and the public, with further impacts anticipated. Case studies provided illustrations of high impact. Conclusions: NBCF’s strategy of investing in a mixed portfolio of research areas and mechanisms encouraged a broad range of impacts across all Payback categories. The impacts from basic research tended to focus on knowledge production and drug development; while applied research generated greater impacts within the other Payback categories. The funding of shared infrastructure stimulated impact across the research system

Humphrey Center News: Spring 1985 v. 1, no. 1

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Summer 1985 v. 1, no. 2

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Spring 1989 v. 4, no. 1

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Fall 1987 v. 2, no. 2

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Fall 1988 v. 3, no. 2

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Spring 1990 v. 5, no. 1

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine

Humphrey Center News: Spring 1988 v. 3, no. 1

Newsletter of the Hubert H. Humphrey Cancer Research Center at Boston University School of Medicine